Cargando…
Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease
BACKGROUND & AIMS: Altered plasma acylcarnitine levels are well-known biomarkers for a variety of mitochondrial fatty acid oxidation disorders and can be used as an alternative energy source for the intestinal epithelium when short-chain fatty acids are low. These membrane-permeable fatty acid i...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694575/ https://www.ncbi.nlm.nih.gov/pubmed/37739064 http://dx.doi.org/10.1016/j.jcmgh.2023.09.005 |
_version_ | 1785153409870987264 |
---|---|
author | Lemons, Johanna M.S. Conrad, Maire Tanes, Ceylan Chen, Jie Friedman, Elliot S. Roggiani, Manuela Curry, Dylan Chau, Lillian Hecht, Aaron L. Harling, Lisa Vales, Jennifer Kachelries, Kelly E. Baldassano, Robert N. Goulian, Mark Bittinger, Kyle Master, Stephen R. Liu, LinShu Wu, Gary D. |
author_facet | Lemons, Johanna M.S. Conrad, Maire Tanes, Ceylan Chen, Jie Friedman, Elliot S. Roggiani, Manuela Curry, Dylan Chau, Lillian Hecht, Aaron L. Harling, Lisa Vales, Jennifer Kachelries, Kelly E. Baldassano, Robert N. Goulian, Mark Bittinger, Kyle Master, Stephen R. Liu, LinShu Wu, Gary D. |
author_sort | Lemons, Johanna M.S. |
collection | PubMed |
description | BACKGROUND & AIMS: Altered plasma acylcarnitine levels are well-known biomarkers for a variety of mitochondrial fatty acid oxidation disorders and can be used as an alternative energy source for the intestinal epithelium when short-chain fatty acids are low. These membrane-permeable fatty acid intermediates are excreted into the gut lumen via bile and are increased in the feces of patients with inflammatory bowel disease (IBD). METHODS: Herein, based on studies in human subjects, animal models, and bacterial cultures, we show a strong positive correlation between fecal carnitine and acylcarnitines and the abundance of Enterobacteriaceae in IBD where they can be consumed by bacteria both in vitro and in vivo. RESULTS: Carnitine metabolism promotes the growth of Escherichia coli via anaerobic respiration dependent on the cai operon, and acetylcarnitine dietary supplementation increases fecal carnitine levels with enhanced intestinal colonization of the enteric pathogen Citrobacter rodentium. CONCLUSIONS: In total, these results indicate that the increased luminal concentrations of carnitine and acylcarnitines in patients with IBD may promote the expansion of pathobionts belonging to the Enterobacteriaceae family, thereby contributing to disease pathogenesis. |
format | Online Article Text |
id | pubmed-10694575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106945752023-12-05 Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease Lemons, Johanna M.S. Conrad, Maire Tanes, Ceylan Chen, Jie Friedman, Elliot S. Roggiani, Manuela Curry, Dylan Chau, Lillian Hecht, Aaron L. Harling, Lisa Vales, Jennifer Kachelries, Kelly E. Baldassano, Robert N. Goulian, Mark Bittinger, Kyle Master, Stephen R. Liu, LinShu Wu, Gary D. Cell Mol Gastroenterol Hepatol Original Research BACKGROUND & AIMS: Altered plasma acylcarnitine levels are well-known biomarkers for a variety of mitochondrial fatty acid oxidation disorders and can be used as an alternative energy source for the intestinal epithelium when short-chain fatty acids are low. These membrane-permeable fatty acid intermediates are excreted into the gut lumen via bile and are increased in the feces of patients with inflammatory bowel disease (IBD). METHODS: Herein, based on studies in human subjects, animal models, and bacterial cultures, we show a strong positive correlation between fecal carnitine and acylcarnitines and the abundance of Enterobacteriaceae in IBD where they can be consumed by bacteria both in vitro and in vivo. RESULTS: Carnitine metabolism promotes the growth of Escherichia coli via anaerobic respiration dependent on the cai operon, and acetylcarnitine dietary supplementation increases fecal carnitine levels with enhanced intestinal colonization of the enteric pathogen Citrobacter rodentium. CONCLUSIONS: In total, these results indicate that the increased luminal concentrations of carnitine and acylcarnitines in patients with IBD may promote the expansion of pathobionts belonging to the Enterobacteriaceae family, thereby contributing to disease pathogenesis. Elsevier 2023-09-20 /pmc/articles/PMC10694575/ /pubmed/37739064 http://dx.doi.org/10.1016/j.jcmgh.2023.09.005 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Lemons, Johanna M.S. Conrad, Maire Tanes, Ceylan Chen, Jie Friedman, Elliot S. Roggiani, Manuela Curry, Dylan Chau, Lillian Hecht, Aaron L. Harling, Lisa Vales, Jennifer Kachelries, Kelly E. Baldassano, Robert N. Goulian, Mark Bittinger, Kyle Master, Stephen R. Liu, LinShu Wu, Gary D. Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease |
title | Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease |
title_full | Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease |
title_fullStr | Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease |
title_full_unstemmed | Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease |
title_short | Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease |
title_sort | enterobacteriaceae growth promotion by intestinal acylcarnitines, a biomarker of dysbiosis in inflammatory bowel disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694575/ https://www.ncbi.nlm.nih.gov/pubmed/37739064 http://dx.doi.org/10.1016/j.jcmgh.2023.09.005 |
work_keys_str_mv | AT lemonsjohannams enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT conradmaire enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT tanesceylan enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT chenjie enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT friedmanelliots enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT roggianimanuela enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT currydylan enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT chaulillian enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT hechtaaronl enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT harlinglisa enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT valesjennifer enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT kachelrieskellye enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT baldassanorobertn enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT goulianmark enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT bittingerkyle enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT masterstephenr enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT liulinshu enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease AT wugaryd enterobacteriaceaegrowthpromotionbyintestinalacylcarnitinesabiomarkerofdysbiosisininflammatoryboweldisease |